<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4359">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603651</url>
  </required_header>
  <id_info>
    <org_study_id>18165</org_study_id>
    <secondary_id>J2X-MC-Y001</secondary_id>
    <nct_id>NCT04603651</nct_id>
  </id_info>
  <brief_title>Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19</brief_title>
  <official_title>Expanded Access Information for Physicians for Bamlanivimab (LY3819253) Emergency Investigational New Drug [EIND]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbCellera Biologics Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The treating physician/investigator contacts Lilly when, based on their medical opinion, a&#xD;
      patient meets the criteria for inclusion in the expanded access program.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>COVID-19</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bamlanivimab</intervention_name>
    <description>Administered intravenously (IV).</description>
    <other_name>LY3819253</other_name>
    <other_name>LY-CoV555</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Reside in a country where there are ongoing Lilly-sponsored clinical trials (currently&#xD;
             this is only the United States)&#xD;
&#xD;
          -  Present within 10 days of symptom onset&#xD;
&#xD;
          -  Have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by reverse&#xD;
             transcription polymerase chain reaction (RT-PCR) within the last three days&#xD;
&#xD;
          -  Participants greater than or equal to (≥) 65 years of age OR&#xD;
&#xD;
          -  Participants ≥ 12 years of age who weigh at least 40 kilograms AND have at least one&#xD;
             of the following:&#xD;
&#xD;
               -  Cancer&#xD;
&#xD;
               -  Chronic kidney disease&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease (COPD) or other chronic lung disease&#xD;
&#xD;
               -  Immunocompromised state (weakened immune system or on immunomodulatory&#xD;
                  medications)&#xD;
&#xD;
               -  Obesity (body mass index [BMI] of 35 or higher)&#xD;
&#xD;
               -  Serious heart conditions such as heart failure, coronary artery disease or&#xD;
                  cardiomyopathies&#xD;
&#xD;
               -  Sickle cell disease&#xD;
&#xD;
               -  Diabetes mellitus (Types 1 or 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Require hospitalization greater than (&gt;) 24 hours or hospice care. Residents in long&#xD;
             term care or skilled nursing facilities that meet the inclusion criteria and are not&#xD;
             on mechanical ventilation will be considered&#xD;
&#xD;
          -  Bamlanivimab should not be used in patients hospitalized with severe COVID-19&#xD;
             respiratory disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Contact Lilly at 1-800-LillyRx (1-800-545-5979)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <verification_date>February 1, 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

